

Boston Scientific

Boston Scientific Announces European Approval for World's First Next-Generation Drug-Eluting Stent System

(September 8, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received CE Mark for its TAXUS® Liberté™ paclitaxel-eluting stent system, the world

<https://news.bostonscientific.com/news-releases?item=58674>